TrialAnnals of surgical oncology2021
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
Saam A Mojtahed et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it